loading
Travere Therapeutics Inc stock is traded at $20.29, with a volume of 546.21K. It is down -5.23% in the last 24 hours and up +0.30% over the past month. Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.
See More
Previous Close:
$21.40
Open:
$21.44
24h Volume:
546.21K
Relative Volume:
0.39
Market Cap:
$1.85B
Revenue:
$203.45M
Net Income/Loss:
$-351.45M
P/E Ratio:
-4.4593
EPS:
-4.55
Net Cash Flow:
$-369.41M
1W Performance:
-4.47%
1M Performance:
+0.30%
6M Performance:
+111.25%
1Y Performance:
+157.69%
1-Day Range:
Value
$20.23
$21.98
1-Week Range:
Value
$20.23
$21.98
52-Week Range:
Value
$5.12
$25.29

Travere Therapeutics Inc Stock (TVTX) Company Profile

Name
Name
Travere Therapeutics Inc
Name
Phone
888-969-7879
Name
Address
3611 VALLEY CENTRE DR, SAN DIEGO
Name
Employee
385
Name
Twitter
Name
Next Earnings Date
2024-10-31
Name
Latest SEC Filings
Name
TVTX's Discussions on Twitter

Compare TVTX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
TVTX
Travere Therapeutics Inc
20.29 1.85B 203.45M -351.45M -369.41M -4.55
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
490.10 124.35B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
687.58 75.07B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
633.30 37.96B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
242.11 31.79B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
BNTX
Biontech Se Adr
112.75 27.34B 3.30B -501.07M 1.03B -2.1146

Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-10-25 Initiated Cantor Fitzgerald Overweight
Oct-21-24 Upgrade Wells Fargo Equal Weight → Overweight
Oct-16-24 Initiated Scotiabank Sector Outperform
Sep-09-24 Upgrade Guggenheim Neutral → Buy
Mar-27-24 Downgrade Guggenheim Buy → Neutral
Dec-05-23 Upgrade Citigroup Neutral → Buy
Nov-20-23 Initiated Citigroup Neutral
Sep-22-23 Downgrade Wells Fargo Overweight → Equal Weight
Sep-21-23 Downgrade William Blair Outperform → Mkt Perform
Sep-06-23 Resumed Evercore ISI Outperform
Jul-21-23 Initiated JP Morgan Overweight
Jun-07-23 Resumed Piper Sandler Neutral
May-22-23 Initiated TD Cowen Outperform
May-05-23 Upgrade Bryan Garnier Sell → Neutral
Mar-01-23 Initiated Guggenheim Buy
Feb-21-23 Upgrade Wedbush Neutral → Outperform
Dec-14-22 Initiated Stifel Hold
Dec-05-22 Initiated Wells Fargo Overweight
Sep-21-22 Initiated Bryan Garnier Sell
Jul-14-22 Resumed Canaccord Genuity Buy
Mar-31-22 Initiated Piper Sandler Overweight
Feb-28-22 Initiated H.C. Wainwright Buy
May-26-21 Downgrade Wedbush Outperform → Neutral
View All

Travere Therapeutics Inc Stock (TVTX) Latest News

pulisher
Mar 02, 2025

When the Price of (TVTX) Talks, People Listen - Stock Traders Daily

Mar 02, 2025
pulisher
Feb 28, 2025

JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Travere Therapeutics (NASDAQ:TVTX) Stock - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

20,749 Shares in Travere Therapeutics, Inc. (NASDAQ:TVTX) Purchased by Ieq Capital LLC - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $35.00 at Citigroup - MarketBeat

Feb 28, 2025
pulisher
Feb 27, 2025

Can Ligand's Triple FDA Wins Offset Its $31M Q4 Loss? Revenue Jumps 52% - StockTitan

Feb 27, 2025
pulisher
Feb 27, 2025

Q1 EPS Estimate for Travere Therapeutics Lowered by Analyst - MarketBeat

Feb 27, 2025
pulisher
Feb 27, 2025

Impax Asset Management Group plc Purchases New Stake in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat

Feb 27, 2025
pulisher
Feb 27, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Travere Therapeutics, Inc. (TVTX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 25, 2025

Travere Therapeutics' (TVTX) Overweight Rating Reaffirmed at Cantor Fitzgerald - MarketBeat

Feb 25, 2025
pulisher
Feb 24, 2025

Analyst Expectations For Travere Therapeutics's Future - Benzinga

Feb 24, 2025
pulisher
Feb 24, 2025

Travere Therapeutics to Participate at Upcoming Investor Conferences - The Manila Times

Feb 24, 2025
pulisher
Feb 24, 2025

Can Travere's March Conference Blitz Signal Major Development Updates? 4 Key Events to Watch - StockTitan

Feb 24, 2025
pulisher
Feb 24, 2025

Citi raises Travere Therapeutics price target to $35, maintains buy By Investing.com - Investing.com Canada

Feb 24, 2025
pulisher
Feb 24, 2025

Citi raises Travere Therapeutics price target to $35, maintains buy - Investing.com India

Feb 24, 2025
pulisher
Feb 24, 2025

Travere Therapeutics (NASDAQ:TVTX) Posts Quarterly Earnings Results - MarketBeat

Feb 24, 2025
pulisher
Feb 23, 2025

Travere Therapeutics Skyrockets After Reaching FDA Deal For Kidney Disease Drug - MSN

Feb 23, 2025
pulisher
Feb 23, 2025

Travere Therapeutics, Inc. (TVTX): the Best Performing Pharma Stock So Far in 2025 - Insider Monkey

Feb 23, 2025
pulisher
Feb 22, 2025

Travere Therapeutics price target raised to $30 from $24 at TD Cowen - Yahoo Finance

Feb 22, 2025
pulisher
Feb 22, 2025

Travere Therapeutics, Inc. (NASDAQ:TVTX) Q4 2024 Earnings Call Transcript - Insider Monkey

Feb 22, 2025
pulisher
Feb 22, 2025

Travere Therapeutics Full Year 2024 Earnings: EPS Misses Expectations - Yahoo Finance

Feb 22, 2025
pulisher
Feb 21, 2025

Travere Therapeutics’ Earnings Call Reveals Growth and Challenges - TipRanks

Feb 21, 2025
pulisher
Feb 21, 2025

US FDA approves Mirum Pharma's genetic disorder drug -February 21, 2025 at 12:07 pm EST - Marketscreener.com

Feb 21, 2025
pulisher
Feb 21, 2025

Travere Therapeutics, Inc. SEC 10-K Report - TradingView

Feb 21, 2025
pulisher
Feb 21, 2025

Travere therapeutics chief medical officer sells $60k in stock - MSN

Feb 21, 2025
pulisher
Feb 21, 2025

Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times

Feb 21, 2025
pulisher
Feb 21, 2025

Travere Therapeutics Inc (TVTX) Q4 2024 Earnings Call Highlights: Strong Phil Spari Sales and ... - Yahoo Finance

Feb 21, 2025
pulisher
Feb 21, 2025

Travere Therapeutics Inc (TVTX) Q4 2024 Earnings Call Highlights: Strong Phil Spari Sales and ... By GuruFocus - Investing.com Canada

Feb 21, 2025
pulisher
Feb 20, 2025

Travere Therapeutics Posts Strong 2024 Financial Results - TipRanks

Feb 20, 2025
pulisher
Feb 20, 2025

Earnings call transcript: Travere Therapeutics Q4 2024 sees earnings beat but stock drops - Investing.com

Feb 20, 2025
pulisher
Feb 20, 2025

Compared to Estimates, Travere (TVTX) Q4 Earnings: A Look at Key Metrics - Yahoo Finance

Feb 20, 2025
pulisher
Feb 20, 2025

Travere Therapeutics (TVTX) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance

Feb 20, 2025
pulisher
Feb 20, 2025

Travere: Q4 Earnings Snapshot - San Antonio Express-News

Feb 20, 2025
pulisher
Feb 20, 2025

Travere: Q4 Earnings Snapshot -February 20, 2025 at 04:27 pm EST - Marketscreener.com

Feb 20, 2025
pulisher
Feb 20, 2025

What To Expect From Travere Therapeutics Inc (TVTX) Q4 2024 Earnings - Yahoo Finance

Feb 20, 2025
pulisher
Feb 20, 2025

Travere Therapeutics earnings beat by $0.17, revenue topped estimates - Investing.com Canada

Feb 20, 2025
pulisher
Feb 18, 2025

Travere Therapeutics (TVTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release - MSN

Feb 18, 2025
pulisher
Feb 18, 2025

Entropy Technologies LP Makes New $214,000 Investment in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat

Feb 18, 2025
pulisher
Feb 18, 2025

Travere Therapeutics, Inc. (NASDAQ:TVTX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat

Feb 18, 2025
pulisher
Feb 17, 2025

TVTX Stock Soars to 52-Week High, Reaching $20.36 - MSN

Feb 17, 2025
pulisher
Feb 17, 2025

Curious about Travere (TVTX) Q4 Performance? Explore Wall Street Estimates for Key Metrics - Yahoo Finance

Feb 17, 2025
pulisher
Feb 17, 2025

Travere Therapeutics (TVTX) Projected to Post Earnings on Thursday - MarketBeat

Feb 17, 2025
pulisher
Feb 16, 2025

Leerink Partnrs Has Strong Forecast for TVTX FY2026 Earnings - MarketBeat

Feb 16, 2025
pulisher
Feb 16, 2025

Travere Therapeutics (NASDAQ:TVTX) Given New $45.00 Price Target at Evercore ISI - MarketBeat

Feb 16, 2025
pulisher
Feb 16, 2025

Travere Therapeutics, Inc. (NASDAQ:TVTX) Insider Peter Heerma Sells 3,074 Shares - MarketBeat

Feb 16, 2025
pulisher
Feb 16, 2025

Travere therapeutics director Roy Baynes sells $220,000 in stock - MSN

Feb 16, 2025
pulisher
Feb 15, 2025

Sandra Calvin Sells 54,244 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock - MarketBeat

Feb 15, 2025
pulisher
Feb 15, 2025

William E. Rote Sells 5,200 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock - MarketBeat

Feb 15, 2025
pulisher
Feb 15, 2025

Eric M. Dube Sells 11,375 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock - MarketBeat

Feb 15, 2025
pulisher
Feb 15, 2025

Scotiabank Issues Positive Forecast for Travere Therapeutics (NASDAQ:TVTX) Stock Price - MarketBeat

Feb 15, 2025
pulisher
Feb 15, 2025

Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $45.00 at Canaccord Genuity Group - MarketBeat

Feb 15, 2025
pulisher
Feb 15, 2025

Travere Therapeutics, Inc. (NASDAQ:TVTX) Director Sells $220,000.00 in Stock - MarketBeat

Feb 15, 2025

Travere Therapeutics Inc Stock (TVTX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Travere Therapeutics Inc Stock (TVTX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
REED ELIZABETH E
SVP, GC & CORPORATE SECRETARY
Feb 12 '25
Sale
23.53
8,000
188,240
89,482
Calvin Sandra
SVP, CHIEF ACCOUNTING OFFICER
Feb 11 '25
Option Exercise
16.63
45,000
748,200
78,654
Calvin Sandra
SVP, CHIEF ACCOUNTING OFFICER
Feb 11 '25
Sale
25.00
54,244
1,356,100
54,410
Heerma Peter
CHIEF COMMERCIAL OFFICER
Feb 11 '25
Sale
25.00
3,074
76,850
127,634
Heerma Peter
CHIEF COMMERCIAL OFFICER
Feb 12 '25
Sale
23.53
2,568
60,426
125,066
Dube Eric M
CHIEF EXECUTIVE OFFICER
Feb 11 '25
Sale
24.04
11,375
273,455
419,173
Inrig Jula
CHIEF MEDICAL OFFICER
Feb 12 '25
Sale
23.53
2,568
60,426
89,602
$78.28
price down icon 4.34%
$23.06
price up icon 1.68%
$33.94
price up icon 1.01%
$19.96
price down icon 4.11%
biotechnology ONC
$245.22
price down icon 9.75%
$112.79
price down icon 0.24%
Cap:     |  Volume (24h):